Bristol Myers Squibb’s Zenbexus received first-in-class FDA approval in multiple myeloma, formally positioning the therapy as the lead molecule in the CELMoDs class of cancer drugs. BMS is framing Zenbexus as a successor to parts of its legacy myeloma portfolio as generic competition reshapes the category. Regulators approved Zenbexus in a combination regimen built around the company’s CELMoD mechanism, which involves engaging the body’s cellular machinery to drive degradation of diseased cells. The label also expands the drug’s use alongside standard backbone agents used in second-line care. Industry attention is now shifting to whether subsequent CELMoD programs can replicate Zenbexus’s performance and whether BMS can translate MRD-driven endpoints into longer-term survival outcomes as confirmatory data are prepared. For biotech teams, the decision underscores the FDA’s willingness to clear drugs within a new mechanism category using remission depth and MRD frameworks that can accelerate adoption in difficult-to-treat blood cancers.